Generic Drug News and Research

RSS

Generic Drugs are official nonbrand names by which medicines are known. Generic names usually refer to the chemical name of the drug.

Viewpoints: 'Killing' Medicaid; medicine for mentally ill; 'outrageous' veto of mammogram bill in Calif.

Even as it vigorously defends the constitutionality of the individual mandate, the Obama administration may be complicit in eviscerating Medicaid -; and setting back the broader goal of ensuring that all Americans have access to quality health care.

15 Oct 2011

Teva acquires Cephalon

Teva Pharmaceutical Industries Ltd. announced today that it has completed its acquisition of Cephalon, Inc. The combined company will have a significant presence in over 60 countries and generated approximately $20 billion in revenues on a pro-forma basis for the twelve months ended June 2011.

15 Oct 2011

COPAXONE reduces loss of brain volume in patients with RRMS

Results from a five-year study of treatment-naïve patients with relapsing-remitting multiple sclerosis (RRMS) demonstrated that patients treated with COPAXONE (glatiramer acetate injection) showed significant reduced loss of brain volume compared to patients treated with other disease modifying therapies.

12 Oct 2011

Research roundup: Health disparities; Prescription drug abuse in Medicare Part D; Medicaid's role for HIV patients

Achieving Equity In Health -- This policy brief examines the outlining factors that cause disparities in the health care system and focuses on the October issue of the journal, which is devoted to research on the subject.

7 Oct 2011

Drug combo for breast cancer in post-menopausal women shows promise

Combining two drugs in post-menopausal women with a certain type of advanced breast cancer more than doubled the time they lived without their disease getting worse, a new study data showed.

26 Sep 2011

New York Times examines possible entry into global market of generic drugs for NCDs

The New York Times describes how, as the U.N. begins its meeting on non-communicable diseases (NCDs), Chinese and Indian generic drug makers "say they are on the verge of selling cheaper copies" of costly biotech medications used to treat cancers, diabetes, arthritis and other chronic illnesses.

20 Sep 2011

Teva to invest in CDI for development of novel antiviral drugs

Teva Pharmaceutical Industries Ltd. announced today that it has signed a collaboration option to license and share purchase agreements to invest in Cocrystal Discovery Inc. (CDI), a biopharmaceutical company focused on the discovery and development of novel antiviral therapeutics for the treatment of serious and chronic viral diseases.

16 Sep 2011

Synthon announces European approvals for Eplerenone

Synthon has successfully concluded multiple registration procedures for the cardiovascular drug Eplerenone. Synthon has obtained regulatory clearance for the product in nine European countries, for both 25 and 50 mg film coated tablets.

15 Sep 2011

Top-line results from Teva-Alcobra MG01CI Phase II trial for ADHD

Teva Pharmaceutical Industries Ltd. and Alcobra Ltd. announced today top-line results from a six week, randomized, placebo-controlled, Phase II multi-center study designed to assess the safety and efficacy of MG01CI in adults with attention deficit hyperactivity disorder (ADHD).

7 Sep 2011

Cost of second-line ARVs a 'huge barrier to care' in resource-poor countries

In this U.N. Dispatch blog post, Mark Leon Goldberg, managing editor of the blog, examines the costs of second-line antiretroviral treatments (ARVs), which "are several orders of magnitude more expensive than traditional, first-line ARV treatments" and are a "huge barrier to providing care" for resource-poor countries.

31 Aug 2011

First Edition: August 26, 2011

In today's headlines, reports about presidential politics and health reform -- most notably, Rick Perry's assault on Mitt Romney's Massachusetts record.

26 Aug 2011

Viewpoints: WSJ on 'super committee'; NEJM perspectives on medical devices

At bottom, the recent deal was meant to defer the bedrock choices that need another election or two to resolve while making incremental progress. So the current exercise is about rooting out $1.5 trillion in "savings," which will mean a hodgepodge of changes at the margin, not a rewrite of either entitlements or taxes. If bigger change were possible, Speaker John Boehner and President Obama would have agreed to it.

12 Aug 2011

FDA accepts Teva's NDA for BDP Nasal HFA to treat allergic rhinitis

Teva Pharmaceutical Industries Ltd. today announced that the U.S. Food and Drug Administration has accepted for filing Teva's New Drug Application (NDA) for beclomethasone dipropionate hydrofluoroalkane (BDP Nasal HFA), a nasal aerosol corticosteroid in development for the treatment of seasonal allergic rhinitis (SAR) and perennial allergic rhinitis (PAR).

8 Aug 2011

Medicare prescriptions premiums expected to decrease for seniors

According to an Obama administration announcement last Thursday as the health costs continue to rise, Medicare beneficiaries will see the average price of a Part D drug plan decline slightly next year. This is expected to offer some relief amid pressure to cut the federal health insurance program for the elderly.

8 Aug 2011

Par Pharmaceutical reports second quarter total revenues of $224.2 million

Par Pharmaceutical Companies, Inc. today reported results for the second quarter ended June 30, 2011.

3 Aug 2011

Teva's ZOELY oral contraceptive receives EU Marketing Authorization

Teva Pharmaceutical Industries Ltd announced today that its new oral contraceptive, ZOELY, has received a Marketing Authorization in the European Union (EU) for the prevention of pregnancy.

2 Aug 2011

Dr. Reddy's, FUJIFILM sign MoU to enter partnership in the generic drugs business

FUJIFILM Corporation President and CEO, Shigetaka Komori and Dr. Reddy's Laboratories Ltd. Vice-Chairman and CEO, G V Prasad today signed a Memorandum of Understanding to enter into an exclusive partnership in the generic drugs business for the Japanese market and to establish a joint venture in Japan.

28 Jul 2011

Teva second quarter net sales increase 11% to $4.2 billion

Teva Pharmaceutical Industries Ltd. today reported results for the quarter ended June 30, 2011.

27 Jul 2011

PharmaNet to assist BrainStorm in obtaining FDA approval for ALS human clinical trials

BrainStorm Cell Therapeutics Inc., an innovative developer of adult stem cell technologies and CNS therapeutics, announced today that it has signed an agreement with PharmaNet LLC, an inVentiv Health Company, to assist in the development of the protocol and IND file for submission to the FDA for approval of BrainStorm's ALS human clinical trials in the United States.

26 Jul 2011

Senate Dems push for Medicare drug savings

During a hearing this week, Senate Democrats, including Aging Committee Chairman Herb Kohl, D-Wis., advanced the causes of certain policies to control drug costs and reduce deficit spending.

22 Jul 2011